|
|
8/26/22
|
Sonoma Biotherapeutics Inc has agreed to a long-term lease agreement for a yet-to-be-developed, 83k sf Research and Development (R&D) and Manufacturing Center in Seattle. The center will be located at 501 Elliott Avenue West, a property owned by Office Properties Income Trust and being redeveloped by The RMR Group into Unison Elliott Bay. Sonoma Bio will serve as the anchor tenant kicking off leasing activity at the three-building project.
Sonoma Bio is a clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. The state-of-the-art facility will support the R&D and manufacturing of Sonoma Bio’s pipeline of gene-modified Treg therapies for autoimmune and inflammatory diseases at scale.
Sonoma Bio’s new R&D and Manufacturing Center will include the development and use of cutting-edge technologies and capabilities, from cell selection and genetic modification to intelligent manufacturing automation and information technology systems. The integration of this infrastructure and scientific expertise will enable Sonoma Bio to move efficiently from molecular target identification to in-house full-scale production for multiple products and indications in Phase 2 clinical trials and beyond.
Steve Lico of Cushman & Wakefield and Kris Richey Curtis of JLL represented Sonoma Bio in the transaction. Lico and Richey Curtis have partnered to represent Sonoma Bio since the biotech company’s inception in 2019. Tim Jones and Joe Gowan of JLL serve as the project’s leasing team and represented RMR in the lease.
|
|
 Return to the Archive page
|
|
|
|
|
Printer-friendly Version
Email an Associate
